Immunoliposomes - A promising approach to targeting cancer therapy
Immunoliposomes - A promising approach to targeting cancer therapy
复制标题
DOI：
10.2165/00063030-200115040-00002
复制
发表时间：
2001-01-01
期刊：
影响因子：
6.8
通讯作者：
Bendas, G
中科院分区：
文献类型：
--
作者：
Bendas, G
免疫脂质体（抗体偶联脂质体）已被认为是非常有吸引力的药物靶向系统的化疗癌症治疗。免疫脂质体制备和应用的基本问题，如抗体偶联和免疫脂质体的稳定性和药代动力学已在过去十年中克服。因此，近年来已经描述了一些关于肿瘤靶向的有希望的研究。添加到现有的审查脂质体药物输送，本文侧重于免疫脂质体肿瘤靶向和总结各种实验的免疫脂质体应用在体外和体内的结构脂质体参数，治疗潜力和要求的目标网站。还考虑了与免疫脂质体相关的新的治疗趋势。免疫脂质体的应用，特别是免疫学方面，仍然存在的问题进行了讨论，是可能有助于克服这些障碍的策略。
Immunoliposomes (antibody-coupled liposomes) have been regarded as very attractive drug-targeting systems for chemotherapeutic cancer treatment. Fundamental problems regarding immunoliposome preparation and application such as antibody coupling and immunoliposome stability and pharmacokinetics have been overcome during the last decade. Therefore, several promising studies on tumour targeting have been described in recent years. Adding to existing reviews on liposomal drug delivery, this article focuses on immunoliposome tumour targeting and summarises various experiments of immunoliposome application in vitro and in vivo with respect to structural liposomal parameters, therapeutic potential and the requirements of the target sites. New therapeutic trends related to immunoliposomes are also considered. Remaining problems in immunoliposome application, especially immunological aspects, are discussed, as are strategies that might help to overcome these obstacles.